You are here

  • Home
  • Archive
  • Volume 88, Issue 12
  • Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events

Article metrics

Article menu
Download PDFPDF
Multiple sclerosis
Research paper
Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events

 

Online download statistics by month:

Online download statistics by month: August 2017 to August 2023

AbstractFullPdf
Aug 2017118645129
Sep 20171123102100
Oct 20172243641
Nov 20174437987
Dec 201769110267
Jan 20184697063
Feb 20183173550
Mar 20182343336
Apr 2018961230
May 20182241839
Jun 20181311218
Jul 20181331411
Aug 20187889
Sep 20181091612
Oct 2018115129
Nov 20181291818
Dec 20189044
Jan 20198172
Feb 201988118
Mar 2019103139
Apr 20195131
May 20196058
Jun 20196187
Jul 20195596
Aug 20195852
Sep 20194376
Oct 20195464
Nov 20195120
Dec 20195635
Jan 20205667
Feb 20204238
Mar 20203741
Apr 20205156
May 20203031
Jun 20204862
Jul 20202124
Aug 20203855
Sep 20202353
Oct 20202264
Nov 20202820
Dec 20204154
Jan 20213950
Feb 20218886
Mar 202164108
Apr 202146105
May 20213045
Jun 2021973
Jul 2021645
Aug 2021223
Sep 20211375
Oct 20211920
Nov 20218643
Dec 20217320
Jan 202211111
Feb 20225731
Mar 20225937
Apr 20224821
May 202210520
Jun 20229152
Jul 20224753
Aug 20229223
Sep 20227121
Oct 20226640
Nov 20226073
Dec 20223731
Jan 20236530
Feb 20239132
Mar 20234565
Apr 20236853
May 20233300
Jun 20236011
Jul 20238731
Aug 20234632
Total8804875906